Green Alpha Advisors’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $335K | Buy |
22,930
+1,014
| +5% | +$9.62K | 0.23% | 95 |
|
|
2026
Q2 | $172K | Sell |
21,916
-1,028
| -4% | -$5.03K | 0.12% | 104 |
|
|
2026
Q1 | $80.1K | Sell |
22,944
-4,648
| -17% | -$16.7K | 0.08% | 104 |
|
|
2025
Q4 | $94.4K | Buy |
27,592
+4,817
| +21% | +$21.5K | 0.09% | 112 |
|
|
2025
Q3 | $115K | Sell |
22,775
-6,328
| -22% | -$27.9K | 0.11% | 96 |
|
|
2025
Q2 | $99.8K | Sell |
29,103
-8,347
| -22% | -$20.8K | 0.1% | 103 |
|
|
2025
Q1 | $83.5K | Sell |
37,450
-385
| -1% | -$1.1K | 0.09% | 105 |
|
|
2024
Q4 | $111K | Sell |
37,835
-10,680
| -22% | -$29.7K | 0.09% | 141 |
|
|
2024
Q3 | $126K | Buy |
48,515
+23,806
| +96% | +$66K | 0.1% | 132 |
|
|
2024
Q2 | $73.1K | Sell |
24,709
-3,638
| -13% | -$13.8K | 0.06% | 135 |
|
|
2024
Q1 | $128K | Buy |
28,347
+520
| +2% | +$2.65K | 0.09% | 140 |
|
|
2023
Q4 | $159K | Sell |
27,827
-11,537
| -29% | -$53.5K | 0.11% | 148 |
|
|
2023
Q3 | $181K | Sell |
39,364
-15,051
| -28% | -$91.6K | 0.14% | 145 |
|
|
2023
Q2 | $352K | Buy |
54,415
+6,672
| +14% | +$45.5K | 0.23% | 122 |
|
|
2023
Q1 | $360K | Sell |
47,743
-950
| -2% | -$8.63K | 0.25% | 120 |
|
|
2022
Q4 | $493K | Sell |
48,693
-451
| -0.9% | -$5.21K | 0.41% | 97 |
|
|
2022
Q3 | $486K | Sell |
49,144
-447
| -0.9% | -$4.9K | 0.41% | 109 |
|
|
2022
Q2 | $528K | Buy |
49,591
+15,578
| +46% | +$132K | 0.12% | 125 |
|
|
2022
Q1 | $332K | Buy |
34,013
+5,846
| +21% | +$55.4K | 0.22% | 123 |
|
|
2021
Q4 | $403K | Buy |
28,167
+3,979
| +16% | +$60.4K | 0.27% | 115 |
|
|
2021
Q3 | $485K | Buy |
+24,188
| New | +$428K | 0.33% | 115 |
|
Other funds holding ABCL
Green Alpha Advisors's ABCL Position: Q3 2026 in Review
Green Alpha Advisors increased its AbCellera Biologics (ABCL) stake by 4.6% in Q3 2026, buying an estimated $9.62K and bringing the position to 22,930 shares worth $335K. The position accounts for 0.23% of the portfolio, ranked #95.
Green Alpha Advisors first reported a position in ABCL in Q3 2021 and has held it in 21 quarters since. The position peaked at $528K in Q2 2022. 4 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.
- Green Alpha Advisors held 22,930 shares of AbCellera Biologics worth $335K as of Q3 2026.
- Green Alpha Advisors bought 1,014 AbCellera Biologics shares in Q3 2026, an estimated $9.62K.
- AbCellera Biologics made up 0.23% of Green Alpha Advisors's portfolio in Q3 2026, its #95 holding.
- Green Alpha Advisors first reported a position in AbCellera Biologics in Q3 2021 and has held it in 21 quarters since.
- Green Alpha Advisors's AbCellera Biologics position peaked at $528K in Q2 2022.
- 4 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.
Based on Green Alpha Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.